MetaCap

Cel-Sci (CVM) vs LeonaBio (LONA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LeonaBio (LONA) has outperformed Cel-Sci (CVM) over the past year, losing 56.1% versus a loss of 80.7%. Over five years, LONA leads with a -98.6% price change compared with -99.6% for CVM. LeonaBio is the larger company by market cap ($26.4 million vs $21.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVM-80.67%LONA-56.13%
+166%+35%-96%
Nov 21, 20251 yearNov 20, 2026
CVM-99.63%LONA-98.61%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVM versus LONA key metrics
MetricCVMLONA
Share price$1.21$2.02
Market cap$21.28M$26.41M
1-day change-17.69%-17.89%
YTD return-77.00%-73.32%
1-year return-80.67%-56.13%
5-year return-99.61%-98.55%
EPS (TTM)$-1.69$-22.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-25.41M$-105.61M
52-week high$7.80$14.21
52-week low$0.89$1.91
Distance from 52-week high-84.49%-85.78%
Analyst consensusnonenone
Avg. price target upside+933.06%+757.92%
Average volume231.46K195.37K
Shares outstanding17.59M13.08M
Employees—19
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LONA has outperformed CVM by 24.5 percentage points over the past year.

About Cel-Sci

CVM stock →

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About LeonaBio

LONA stock →

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

CVM vs LONA FAQ

Which is bigger, Cel-Sci or LeonaBio?

LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $21.28M for Cel-Sci (CVM).

Which stock has performed better over the past year, CVM or LONA?

LONA returned -56.13% over the past 12 months, compared with -80.67% for CVM (price return, excluding dividends). Past performance does not predict future results.

Are Cel-Sci and LeonaBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons